Elizabeth Arden (RDEN) 28.05 $RDEN
Elizabeth Arden Brings Rx Skincare Cream - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 28, 1:40PM CDT
Cosmetics retailer Elizabeth Arden is trying to boost sales after reporting unimpressive second-quarter fiscal 2014 results last month.
Elizabeth Arden Introduces Elizabeth Arden Rx
Business Wire - Mon Mar 24, 8:30AM CDT
Elizabeth Arden, Inc. (NASDAQ:RDEN), a global prestige beauty products company, introduces new Elizabeth Arden Rx, a comprehensive professional skincare line developed exclusively for physician offices. Elizabeth Arden Rx addresses four key skin conditions--Anti-Aging, Brightening, Clarifying, and Hydration--combining highly effective in-office treatments and at-home products to provide simple solutions for patients with signs of premature skin aging, uneven skin tone and pigmentation, acne and problem-prone skin and dry dehydrated skin. The at-home products are designed to be used as stand-alone home skincare--as well as enhance, maintain and optimize results between professional treatments--by using proprietary ingredients including several new patent-pending technologies: AHA Retinoid Conjugate, an AHA/Vitamin A derivative combination; Allyl PQQ, a new mitochondrial anti-oxidant; and a novel anti-oxidant complex(1) designed specifically to protect essential skin proteins against harmful degradation.
Elizabeth Arden Forays into Professional Skincare - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 6:15PM CDT
Cosmetics retailer Elizabeth Arden launched the latest Elizabeth Arden Rx skincare line to be available exclusively at physicians' offices.
China's Lipstick Wars
at The Street - Mon Mar 10, 7:41AM CDT
China has all but declared war on cosmetic imports, destroying shipments of health and beauty products from Elizabeth Arden, Johnson & Johnson and Revlon.
Elizabeth Arden Unveils Next Step in Multi-Channel Distribution Strategy
Business Wire - Thu Mar 06, 2:26PM CST
Elizabeth Arden, Inc. (NASDAQ:RDEN), a global prestige beauty products company, announces the launch of its new Elizabeth Arden Rx skincare line, which will be available exclusively in physician offices. This is consistent with the Company's omni-channel growth strategy of selling and marketing Elizabeth Arden branded products in the prestige retail, spa and now the professional skincare market.
Elizabeth Arden Unveils a New Standard in Topical Skincare Protection Triple Protection Factor Broad Spectrum Sunscreen SPF 50+ as Part of New Professional Skincare Line, Elizabeth Arden Rx
PR Newswire - Thu Mar 06, 1:47PM CST
Elizabeth Arden, Inc. today, in tandem with the release of a clinical study published in the Journal of Drugs in Dermatology, unveiled Triple Protection Factor Broad Spectrum Sunscreen SPF 50+, or TPF 50, a groundbreaking new anti-aging product. TPF 50 was developed based on a unique combination of protective and restorative ingredients including a DNA Enzyme Complex, a highly potent protein protection Antioxidant Complex and broad spectrum SPF 50+ sun protection. This combination works synergistically to create the most effective topical skin protection on the market[2]. TPF 50 is the first of a comprehensive new skincare line, Elizabeth Arden Rx, designed for exclusive distribution in physician offices. A key pillar to Elizabeth Arden's omni-channel growth strategy, Elizabeth Arden Rx marks the company's official entry into the global professional skincare market.
Elizabeth Arden Down to Strong Sell - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 25, 3:50PM CST
Zacks Investment Research downgraded Elizabeth Arden Inc. to a Zacks Rank #5 (Strong Sell) on Feb 22, 2014 following weak results in the second quarter fiscal 2013.
29.5% Return Seen to Date on SmarTrend Elizabeth Arden Call (RDEN)
Comtex SmarTrend(R) - Tue Feb 25, 11:08AM CST
SmarTrend identified a Downtrend for Elizabeth Arden (NASDAQ:RDEN) on July 30th, 2013 at $41.99. In approximately 7 months, Elizabeth Arden has returned 29.50% as of today's recent price of $29.60.
Elizabeth Arden Down 32.8% Since SmarTrend Downtrend Call (RDEN)
Comtex SmarTrend(R) - Tue Feb 18, 9:41AM CST
SmarTrend identified a Downtrend for Elizabeth Arden (NASDAQ:RDEN) on July 30th, 2013 at $41.99. In approximately 7 months, Elizabeth Arden has returned 32.81% as of today's recent price of $28.21.
Bear of the Day: Elizabeth Arden (RDEN) - Bear of the Day
Eric Dutram - ZACKS - Fri Feb 14, 2:43AM CST
Bear of the Day: Elizabeth Arden (RDEN) - Bear of the Day
Falling Earnings Estimates Signal Weakness Ahead for Elizabeth Arden (RDEN) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 12, 7:35AM CST
Elizabeth Arden has witnessed a significant price decline in the past four weeks and negative earnings estimate revisions for the current quarter and the current year, making it time for investors to sell it off
Luxury Stocks: Can Brands Grow In China By Focusing On Women?
at The Street - Tue Feb 11, 4:17PM CST
James Dennin, Kapitall: Luxury stocks for men have been hammered in the Chinese market. Do women's luxury brands have room to grow? [...]
Holding Onto This Beauty Retailer Is Not a Good Idea
Pratik Thacker, The Motley Fool - Motley Fool - Mon Feb 10, 11:20AM CST
Heavy promotions are key for retailers during the holiday season. This is especially true when people are less willing to open their wallets. Moreover, when all of the other industry players promote their products and provide deep discounts to...
38.7% Return Seen to Date on SmarTrend Elizabeth Arden Call (RDEN)
Comtex SmarTrend(R) - Mon Feb 10, 11:00AM CST
SmarTrend identified a Downtrend for Elizabeth Arden (NASDAQ:RDEN) on July 30th, 2013 at $41.99. In approximately 7 months, Elizabeth Arden has returned 38.69% as of today's recent price of $25.74.
Elizabeth Arden (RDEN) Crumbles: Stock Falls by 6.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Feb 06, 7:52AM CST
Elizabeth Arden saw a big move last session on pretty good volume with far more shares changing hands than in a normal session; shares fell over 6% on the day.
Estee Lauder, Elizabeth Arden's 2Q show challenges
AP - Wed Feb 05, 1:06PM CST
NEW YORK (AP) — Two of the nation's top cosmetic companies reported their fiscal second-quarter results Wednesday that reflect a challenging environment.
Elizabeth Arden, Inc. Announces Second Quarter Fiscal 2014 Results
Business Wire - Wed Feb 05, 5:59AM CST
Elizabeth Arden, Inc. (NASDAQ:RDEN), a global prestige beauty products company, announced today financial results for its second fiscal quarter ended December 31, 2013.
Downtrend Call Working As Elizabeth Arden Stock Falls 36.6% (RDEN)
Comtex SmarTrend(R) - Mon Feb 03, 9:38AM CST
SmarTrend identified a Downtrend for Elizabeth Arden (NASDAQ:RDEN) on July 30th, 2013 at $41.99. In approximately 6 months, Elizabeth Arden has returned 36.57% as of today's recent price of $26.63.
Elizabeth Arden Brings Rx Skincare Cream - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 28, 1:40PM CDT
Cosmetics retailer Elizabeth Arden is trying to boost sales after reporting unimpressive second-quarter fiscal 2014 results last month.
Elizabeth Arden Introduces Elizabeth Arden Rx
Business Wire - Mon Mar 24, 8:30AM CDT
Elizabeth Arden, Inc. (NASDAQ:RDEN), a global prestige beauty products company, introduces new Elizabeth Arden Rx, a comprehensive professional skincare line developed exclusively for physician offices. Elizabeth Arden Rx addresses four key skin conditions--Anti-Aging, Brightening, Clarifying, and Hydration--combining highly effective in-office treatments and at-home products to provide simple solutions for patients with signs of premature skin aging, uneven skin tone and pigmentation, acne and problem-prone skin and dry dehydrated skin. The at-home products are designed to be used as stand-alone home skincare--as well as enhance, maintain and optimize results between professional treatments--by using proprietary ingredients including several new patent-pending technologies: AHA Retinoid Conjugate, an AHA/Vitamin A derivative combination; Allyl PQQ, a new mitochondrial anti-oxidant; and a novel anti-oxidant complex(1) designed specifically to protect essential skin proteins against harmful degradation.
Elizabeth Arden Forays into Professional Skincare - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 6:15PM CDT
Cosmetics retailer Elizabeth Arden launched the latest Elizabeth Arden Rx skincare line to be available exclusively at physicians' offices.
China's Lipstick Wars
at The Street - Mon Mar 10, 7:41AM CDT
China has all but declared war on cosmetic imports, destroying shipments of health and beauty products from Elizabeth Arden, Johnson & Johnson and Revlon.
Elizabeth Arden Unveils Next Step in Multi-Channel Distribution Strategy
Business Wire - Thu Mar 06, 2:26PM CST
Elizabeth Arden, Inc. (NASDAQ:RDEN), a global prestige beauty products company, announces the launch of its new Elizabeth Arden Rx skincare line, which will be available exclusively in physician offices. This is consistent with the Company's omni-channel growth strategy of selling and marketing Elizabeth Arden branded products in the prestige retail, spa and now the professional skincare market.
Elizabeth Arden Unveils a New Standard in Topical Skincare Protection Triple Protection Factor Broad Spectrum Sunscreen SPF 50+ as Part of New Professional Skincare Line, Elizabeth Arden Rx
PR Newswire - Thu Mar 06, 1:47PM CST
Elizabeth Arden, Inc. today, in tandem with the release of a clinical study published in the Journal of Drugs in Dermatology, unveiled Triple Protection Factor Broad Spectrum Sunscreen SPF 50+, or TPF 50, a groundbreaking new anti-aging product. TPF 50 was developed based on a unique combination of protective and restorative ingredients including a DNA Enzyme Complex, a highly potent protein protection Antioxidant Complex and broad spectrum SPF 50+ sun protection. This combination works synergistically to create the most effective topical skin protection on the market[2]. TPF 50 is the first of a comprehensive new skincare line, Elizabeth Arden Rx, designed for exclusive distribution in physician offices. A key pillar to Elizabeth Arden's omni-channel growth strategy, Elizabeth Arden Rx marks the company's official entry into the global professional skincare market.
Elizabeth Arden Down to Strong Sell - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 25, 3:50PM CST
Zacks Investment Research downgraded Elizabeth Arden Inc. to a Zacks Rank #5 (Strong Sell) on Feb 22, 2014 following weak results in the second quarter fiscal 2013.
29.5% Return Seen to Date on SmarTrend Elizabeth Arden Call (RDEN)
Comtex SmarTrend(R) - Tue Feb 25, 11:08AM CST
SmarTrend identified a Downtrend for Elizabeth Arden (NASDAQ:RDEN) on July 30th, 2013 at $41.99. In approximately 7 months, Elizabeth Arden has returned 29.50% as of today's recent price of $29.60.
Elizabeth Arden Down 32.8% Since SmarTrend Downtrend Call (RDEN)
Comtex SmarTrend(R) - Tue Feb 18, 9:41AM CST
SmarTrend identified a Downtrend for Elizabeth Arden (NASDAQ:RDEN) on July 30th, 2013 at $41.99. In approximately 7 months, Elizabeth Arden has returned 32.81% as of today's recent price of $28.21.
Bear of the Day: Elizabeth Arden (RDEN) - Bear of the Day
Eric Dutram - ZACKS - Fri Feb 14, 2:43AM CST
Bear of the Day: Elizabeth Arden (RDEN) - Bear of the Day
Falling Earnings Estimates Signal Weakness Ahead for Elizabeth Arden (RDEN) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 12, 7:35AM CST
Elizabeth Arden has witnessed a significant price decline in the past four weeks and negative earnings estimate revisions for the current quarter and the current year, making it time for investors to sell it off
Luxury Stocks: Can Brands Grow In China By Focusing On Women?
at The Street - Tue Feb 11, 4:17PM CST
James Dennin, Kapitall: Luxury stocks for men have been hammered in the Chinese market. Do women's luxury brands have room to grow? [...]
Holding Onto This Beauty Retailer Is Not a Good Idea
Pratik Thacker, The Motley Fool - Motley Fool - Mon Feb 10, 11:20AM CST
Heavy promotions are key for retailers during the holiday season. This is especially true when people are less willing to open their wallets. Moreover, when all of the other industry players promote their products and provide deep discounts to...
38.7% Return Seen to Date on SmarTrend Elizabeth Arden Call (RDEN)
Comtex SmarTrend(R) - Mon Feb 10, 11:00AM CST
SmarTrend identified a Downtrend for Elizabeth Arden (NASDAQ:RDEN) on July 30th, 2013 at $41.99. In approximately 7 months, Elizabeth Arden has returned 38.69% as of today's recent price of $25.74.
Elizabeth Arden (RDEN) Crumbles: Stock Falls by 6.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Feb 06, 7:52AM CST
Elizabeth Arden saw a big move last session on pretty good volume with far more shares changing hands than in a normal session; shares fell over 6% on the day.
Estee Lauder, Elizabeth Arden's 2Q show challenges
AP - Wed Feb 05, 1:06PM CST
NEW YORK (AP) — Two of the nation's top cosmetic companies reported their fiscal second-quarter results Wednesday that reflect a challenging environment.
Elizabeth Arden, Inc. Announces Second Quarter Fiscal 2014 Results
Business Wire - Wed Feb 05, 5:59AM CST
Elizabeth Arden, Inc. (NASDAQ:RDEN), a global prestige beauty products company, announced today financial results for its second fiscal quarter ended December 31, 2013.
Downtrend Call Working As Elizabeth Arden Stock Falls 36.6% (RDEN)
Comtex SmarTrend(R) - Mon Feb 03, 9:38AM CST
SmarTrend identified a Downtrend for Elizabeth Arden (NASDAQ:RDEN) on July 30th, 2013 at $41.99. In approximately 6 months, Elizabeth Arden has returned 36.57% as of today's recent price of $26.63.
